Summit Therapeutics (SMMT) director reports new stock option grants

Rhea-AI Filing Summary

Summit Therapeutics Inc. director Robert F. Booth reported receiving two stock option grants on January 2, 2026. He was granted stock options to purchase 35,000 shares of common stock at an exercise price of $17.52 per share, expiring on January 2, 2036. These options vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, as long as he remains a non-salaried director on each vesting date.

Booth was also granted stock options covering 7,180 shares of common stock, also at an exercise price of $17.52 per share and expiring on January 2, 2036. These options vest in four quarterly installments on March 31, June 30, September 30 and December 31 following his election as a director and were issued under the company’s Director Retainer Option Election Plan in lieu of $62,900 in retainer fees.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Robert F.

(Last) (First) (Middle)

C/O SUMMIT THERAPEUTICS INC.

601 BRICKELL KEY DRIVE, SUITE 1000

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$17.52	01/02/2026		A		35,000		(1)	01/02/2036	Common Stock	35,000	(2)	35,000	D
Stock Option (right to buy)	$17.52	01/02/2026		A		7,180		(3)	01/02/2036	Common Stock	7,180	$8.76(4)	7,180	D

Explanation of Responses:

1. The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date.

2. Not applicable.

3. The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date.

4. The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $62,900.

Remarks:

	/s/ Bhaskar Anand, as Attorney-in-Fact for Robert Booth	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Summit Therapeutics (SMMT) report for director Robert Booth?

The filing reports that director Robert F. Booth received two grants of stock options on January 2, 2026: one for 35,000 options and another for 7,180 options, both exercisable for Summit Therapeutics common stock.

What are the key terms of Robert Booths 35,000 Summit Therapeutics stock options?

The 35,000 stock options have an exercise price of $17.52 per share and expire on January 2, 2036. They vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, contingent on Booth remaining a non-salaried director on each vesting date.

How do the 7,180 Summit Therapeutics stock options granted to Robert Booth vest?

The 7,180 stock options also carry a $17.52 exercise price and an expiration date of January 2, 2036. They vest in four quarterly installments on March 31, June 30, September 30 and December 31 following Booths election, subject to him remaining a non-salaried director on each vesting date.

Why did Summit Therapeutics grant 7,180 stock options to Robert Booth?

The 7,180 stock options were issued to Robert Booth under the issuers Director Retainer Option Election Plan in lieu of $62,900 in retainer fees, effectively replacing cash compensation with equity-based compensation.

Are Robert Booths Summit Therapeutics stock options held directly or indirectly?

According to the filing data, the stock options reported for Robert F. Booth are held with direct (D) ownership, with no separate entity or indirect ownership structure disclosed.

What is the significance of the January 2, 2036 expiration date on Robert Booths options?

Both option grants to Robert Booth have an expiration date of January 2, 2036, meaning he may exercise the vested portions of these options any time up to that date, subject to the plan terms and his continued service as a non-salaried director for vesting.